Commentary - 15/02/21
Funding source: Supported in part by National Institute of Arthritis and Musculoskeletal and Skin Diseases grant P30AR069589-03 (to George Cotsarelis, MD). |
|
Conflicts of interest: Dr Gelfand served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (Data Safety and Monitoring Board), Sanofi, and Pfizer Inc, receiving honoraria; in addition, he receives research grants (to the Trustees of the University of Pennsylvania) from Abbvie, Janssen, Novartis Corp, Sanofi, Celgene, Ortho Dermatologics, and Pfizer Inc, and he has received payment for CME work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics. In addition, Dr Gelfand is a copatent holder of resiquimod for treatment of cutaneous T cell lymphoma, and he is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology. |
|
Dr Syed is supported in part by a grant from Pfizer. Dr Shin has no conflicts of interest to declare. |
|
IRB approval status: Not applicable. |
Vol 84 - N° 3
P. e161-e162 - mars 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?